Medical Oncology

The SWOG 1801 trial showed improved event-free survival (EFS) in patients receiving neoadjuvant pembrolizumab followed by 15 cycles of adjuvant pembro...

1 Answer available

What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?

Do you prefer single agent PD-1 inhibitor or combination immunotherapy?

1 Answer available

How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?

Very-low-risk stage IIIA disease includes non-ulcerated lesions, primary ≤2 mm thickness, SLN metastasis <1 mm. Per NCCN the toxicity of adjuvan...

1 Answer available

How do you approach an elderly patient (~80 years) with stage IIC melanoma post resection with oligometastatic brain lesion post intracranial resection which developed 2 years after treatment?

The patient's current PET scan showed no systemic disease. Due to his age, there is a concern of whether the patient would tolerate dual immunotherapy...

2 Answers available

How would you treat an elderly patient (ECOG 0-1) with locally advanced rectal cancer and synchronous Merkel cell cancer of the extremity requiring adjuvant RT?

Would you treat both at the same time? Does one need to be prioritized over the other? Does Xeloda have any efficacy against Merkel cell cancer? How...

4 Answers available

What surveillance plan would you recommend for stage IV melanoma patients who achieve a CR or stable PR response with immunotherapy?

1 Answer available

How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?

Is there a potential role for concurrent radiation therapy? What if the tumor is BRAF mutated?

2 Answers available

What surveillance imaging do you obtain for stage III melanoma patients after completing systemic adjuvant therapy?

1 Answer available

How do you approach patients with metastatic uveal melanoma not a candidate for tebentafusp-tebn?

2 Answers available

How would you manage a localized melanoma of the anal canal with sphincter involvement, but without nodal or distant disease?

1 Answer available

How do you approach patients with malignant melanoma who are disease free on immunotherapy for over 3 years?

1 Answer available

How do you approach patients with stage III melanoma for adjuvant treatment?

Which group of patients will benefit with observation versus adjuvant immunotherapy?

1 Answer available

How do you approach patients with polypoid/nodular melanoma for adjuvant therapy when Breslow depth is not available on pathology?

In this scenario do we use the actual tumor size for "T staging".

2 Answers available

How do you approach the management of basal cell carcinoma with single lymph node involvement?

In patients with no apparent skin involvement but lymph-node showing basal cell carcinoma with extracapsular extension. Would this warrant radiation o...

3 Answers available

Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?

Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?

4 Answers available

Would you continue cemiplimab or pembrolizumab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma?

Do you base your decision on extent of residual disease? Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...

4 Answers available

Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?

Is a placebo-controlled trial anticipated?

6 Answers available

Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?

3 Answers available

How do you approach patients with a new primary melanoma, not an in-transit metastasis, while on adjuvant immunotherapy/treatment for a previous melanoma lesion?

2 Answers available

How do you approach patients with early stage resected melanoma (Stage IIA) for adjuvant treatment?

1 Answer available

What scenario would prophylactic Tocilizumab be considered to prevent Ipilimumab+Nivolumab (immunotherapy) induced toxicity in malignant melanoma?

1 Answer available

What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?

3 Answers available

How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?

If the patient had no nodal sampling, would this influence your decision?

1 Answer available

What scenario would flipped dosing versus standard dosing of ipilimumab + nivolumab be beneficial in metastatic melanoma?

CheckMate 511 trial showed reduced toxicity with flipped dosing of ipilimumab/ nivolumab (ipi 1 mg/kg and nivo 3 mg/kg instead of ipi 3 mg/kg and nivo...

1 Answer available

What is your next step in management for a patient with immunotherapy induced pneumonitis that does not improve on high dose steroids for 48 hours?

How do you decide between starting infliximab, MMF, or IVIG? If a patient presents in respiratory failure (nearing or requiring intubation), woul...

1 Answer available

How do you approach patients with recurrent BRAF negative melanoma and resected oligo-metastasis after completing one year of adjuvant nivolumab?

1 Answer available

In what scenario would you add systemic therapy with adjuvant radiation therapy in resected, locally-advanced, cutaneous squamous cell carcinoma?

Reference: TROG 05.01 Trial

1 Answer available

Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?

1 Answer available

Do you get routine MRI brain for surveillance on patients with history of stage III melanoma?

2 Answers available

In what scenario would you consider dual IO and TKI therapy in advanced stage melanoma?

1 Answer available

Is there benefit in switching between sonedegib to vismodegib or vice versa for patients with unresectable basal cell carcinoma of the face that progresses on first line hedgehog inhibitor?

2 Answers available

When treating patients with immune checkpoint inhibitors, do you routinely check markers of endocrinopathies such as TSH/ACTH, or only when a patient has symptoms?

If so, how often do you check these labs?

1 Answer available

Based on the results of SWOG S1801, neoadjuvant vs adjuvant pembrolizumab for resected stage IIIB-IV melanoma, are you starting to recommend neoadjuvant pembro for your patients?

ESMO Congress 2022 Abstract

2 Answers available

Among the metastatic/unresectable melanoma patients you would historically treat with anti-PD-1 monotherapy, are you now recommending nivolumab/relatlimab instead?

1 Answer available

What are your top takeaways in Melanoma from ASCO 2022?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

1 Answer available

Which patients with cSCC could you omit adjuvant radiation following pathologic complete response following cemiplimab?

1 Answer available

Do you stop PPI when starting patients on immunotherapy?

1 Answer available

If a BRAF-mutated melanoma patient developed metastatic disease progression on adjuvant anti-PD-1 monotherapy, do you recommend switching to BRAF/MEK targeted therapy or combination nivolumab/ipilimumab?

2 Answers available

How would you manage a resectable satellite/in-transit melanoma recurrence that developed during adjuvant immunotherapy?

1 Answer available

What immunosuppressive agents would be available to patients with a history of melanoma?

Would you use immunosuppression in patients several years after curative treatment for melanoma?

1 Answer available

How would you manage a nodal recurrence of cutaneous SCC if the patient is unable to receive surgery for 6-8 weeks?

In a patient who would be otherwise fit for surgery +/- adjuvant RT, and the delay is caused by COVID-related OR staffing issues, what would be your a...

1 Answer available

How do you recommend differentiating between localized cutaneous melanoma of the perianal skin versus mucosal melanoma of anal canal?

This question arises from a case of a patient with multifocal nodular melanoma with circumferential involvement of the perianal region.

1 Answer available

What is your preferred first-line treatment for metastatic melanoma in a patient with a class 2/non-V600 BRAF mutation?

4 Answers available

What is your preferred adjuvant treatment option for a patient with stage III BRAF-mutated melanoma and a history of a solid organ transplantation on immunosuppressants?

0 Answers available

Would you offer adjuvant immunotherapy for a melanoma patient with lymphocytic colitis?

1 Answer available

How would you approach an early inguinal recurrence after surgical resection of Merkel Cell carcinoma in the popliteal region?

2 Answers available

Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

3 Answers available

Would you pursue adjuvant immunotherapy for a resected stage IIIC or IIID, BRAF wild type, melanoma patient with pre-existing ulcerative colitis that is well managed on maintenance infliximab?

1 Answer available

What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?

Based on available results from the IMMUNED trial, which evaluated the role of adjuvant nivolumab/ipilimumab or nivolumab monotherapy vs placebo in re...

2 Answers available

What type of surveillance would you recommend following resection of primary mucinous carcinoma of the skin?

1 Answer available

How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?

If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?

1 Answer available

How do you manage MEK inhibitor induced ocular adverse events?

1 Answer available

When, if ever, would you consider using encorafenib/binimetinib or vemurafenib/cobimetinib instead of dabrafenib/trametinib for adjuvant treatment of BRAF mutated melanoma?

0 Answers available

Would you start neoadjuvant treatment with immunotherapy or BRAF/MEK inhibitors in a patient with a large regional inoperable BRAF V600E positive melanoma (IIIC)?

1 Answer available

Is there a role for adjuvant therapy, either radiation (+/- chemo), or systemic therapies (immunotherapy, targeted agents or chemotherapy) after resection of anorectal mucosal melanoma?

1 Answer available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?

1 Answer available

How do you decide between initial radiotherapy vs systemic therapy in patients with metastatic melanoma and brain metastases?

If neurologic symptoms are absent or controlled, does that affect your treatment decision?

2 Answers available

Would you consider starting immunotherapy concurrently with whole brain radiation for newly diagnosed metastatic (BRAF negative) melanoma with multifocal symptomatic brain metastases?

If so, would you consider it with monotherapy only or also with combined checkpoint blockade?

2 Answers available

Do you ever recommend concurrent chemotherapy for high risk squamous cell skin cancer radiation?

What dose of radiation, what type of chemo, and what indications?

2 Answers available

When do you change treatment for an asymptomatic metastatic melanoma with a mixed response after at least 3 months of treatment with a PD-L1 inhibitor?

1 Answer available

Is there any contraindication to concurrent administration of radioactive iodine in a patient on immunotherapy?

A patient with stage 3 melanoma on adjuvant nivolumab needs radioactive iodine for papillary thyroid cancer.

1 Answer available

Would you offer concurrent chemoradiotherapy and/or adjuvant systemic therapy (chemo or immunotherapy) or for a completely resected stage III Merkel cell after WLE and ALND?

Patient is a 67yo with a pT1 (2.5mm) pN1a merkel cell of the chest, 1 mm deep, widely clear margins, SLN with 1.5mm met, 11 additional axillary ...

2 Answers available

For a patient with limited/resectable metastatic melanoma and no evidence of disease after resection, when would you consider doublet immunotherapy rather than nivolumab or pembrolizumab monotherapy?

For instance, in a patient with isolated distant nodal involvement who had the lymph node resected but did not have a lymph node dissection?

1 Answer available

How do you manage local recurrence of a resected stage III BRAF WT melanoma occurring during or shortly after completion of adjuvant nivolumab?

Would you offer nodal dissection and/or additional adjuvant immunotherapy in addition to wide local excision?

1 Answer available

How do you decide whether or not to give immunotherapy in patients with a history of an isolated, severe autoimmune event?

For instance, not chronic autoimmune diseases (eg RA, IBD) that may relapse/remit but events like Guillan Barre syndrome that is not likely to recur b...

1 Answer available

What therapy would you offer a young BRAF wild type patient with metastatic melanoma, who progressed on single agent pembrolizumab?

1 Answer available

How do your adjuvant treatment recommendations change, if at all, for clinically node positive Stage III desmoplastic melanoma?

1 Answer available

How would you treat a patient with BRAF mutated Metastatic Melanoma who has progressed on targeted therapy (Encorafenib + Binimetinib) and Immuotherapy (Nivolumab/Ipilimumab), but yet maintain an excellent performance status?

2 Answers available

Can you use immunotherapy in patients with liver transplants?

With increasing utility of immunotherapy across cancer types, patients with history of solid organ transplants may face need for cancer IO. How do you...

1 Answer available

When do you consider employing the 4-week dosing schedule for nivolumab?

The FDA has approved the new dosing schedule of Nivolumab 480 mg every 4 weeks for multiple disease sites (melanoma, RCC, urothelial carcinoma, SCC of...

5 Answers available

What are your recommendation for vaccines in patients while on immunotherapy?

Do you recommend or withhold influenza and pneumonia vaccines while on treatment with checkpoint inhibitors?

1 Answer available

Would you give adjuvant nivolumab for IIIA melanoma?

Patients with T3aN1a( stage IIIA per AJCC7) were excluded from nivolumab adjuvant trial. Would you consider nivolumab in these patients?

1 Answer available

How would you approach a patient who progressed on immunotherapy for merkel cell carcinoma?

Checkpoint inhibitors have demonstrated durable responses in clinical trials, which was never seen with cytotoxic chemotherapy in the past. What are t...

1 Answer available

What is your approach to metastatic choroidal melanoma with systemic metastases outside of a clinical trial?

NCCN guidelines recommend both single agent Pembro and/or Ipi/Nivo as first line options. How would you choose between the two? In case of the latter,...

1 Answer available

What is the role of Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma?

The FDA recently approved Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma. When would they be ...

1 Answer available

How would you treat a patient with aggressive metastatic cutaneous squamous cell carcinoma, which is not amenable to surgery or radiation?

2 Answers available

When would you consider neoadjuvant immunotherapy for advanced melanoma?

For example, would you consider this in a patient that would otherwise be eligible for adjuvant treatment (stage III or stage IV with oligometastatic ...

1 Answer available

Would you hold immunotherapy if a patient with metastatic melanoma has stable disease for 6 months?

If so, after what duration?

1 Answer available

Would you consider stopping nivo/ipi combination after a CR in a patient with metastatic melanoma?

Can you extrapolate the data on Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma to patients on a...

1 Answer available

What is the your choice of treatment after progression or AE following pembrolizumab in metastatic melanoma?

Patient does not have BRAF mutation.

1 Answer available

Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?

In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive?

1 Answer available

What is your approach to the initial treatment of metastatic melanoma patients with NRAS mutations?

How do you treat these patients if they progress after immune checkpoint inhibitors?

1 Answer available

What systemic therapy, if any, would you recommend for a patient with oligometastatic melanoma who is rendered NED after resection?

Would your recommendation change at all depending on time to relapse or original stage of melanoma?

1 Answer available

What would you recommend as adjuvant treatment for a patient with Stage III melanoma?

If staged so due to satellite lesion and negative nodes? How do you decide between adjuvant PD-1 inhibitor or BRAF/MEK inhibition in BRAF-mutated pati...

1 Answer available

What treatment would you offer to a patient after resection of a solitary metastatic melanoma from the brain without evidence of other sites of disease?

Assuming SRS to the resection cavity is advised, would you recommend early immunotherapy to improve outcomes/enhance a possible abscopal eff...

1 Answer available

Is there a role for PD-1 inhibitors for metastatic or locally recurrent cutaneous squamous cell carcinomas after failure of first line therapy, EGFR inhibitors?

Is it commonly used if no clinical trials are available?

1 Answer available

Would you treat a patient with HIV or hepatitis C with an anti-PD-1 agent?

These patients have been largely excluded from these trials. What if the infection is well controlled?

3 Answers available

Is it necessary to hold immunotherapy during a 4-6wk steroid taper after resolution of immunotherapy related toxicity?

Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...

1 Answer available

How do you approach treatment for metastatic cutaneous squamous cell carcinoma after standard chemotherapy failure?

Is the use of immunotherapy being considered, and if so, is the data extrapolated from treatment of mNSCLC and head and neck SCC?

1 Answer available

Do you consider alternate therapy with a different anti-PD1 agent after a patient responds to an anti-CTLA4 +/- anti-PD1 agent but develops serious side effects?

Is there data for switching from nivolumab/ipilimumab to pembrolizumab if a patient develops significant pneumonitis but also had a significant radiog...

1 Answer available

Does anaphylactoid reaction to one immunotherapy agent exclude the possibility of using other immunotherapy agents?

1 Answer available

Do you resume immunotherapy (such as nivolumab) for metastatic melanoma after therapy-induced grade 4 hyperglycemia that has resolved?

Can immune check point inhibitor be restarted if grade 4 hyperglycemia (with acidosis and insulin drip requirement) has resolved?

1 Answer available

Is there an effective treatment for multiple appearances of cutaneous Kaposi's lesions besides radiation?

In a patient who already received 13 courses of radiation (with complete response), is there any other effective treatment?

1 Answer available

Would you start immunotherapy in a patient with metastatic melanoma who is on steroids (e.g. dexamethasone for cerebral edema)?

Or would you try to wait and get the steroids off first?

1 Answer available

How do you approach the management of surgically resected conjunctival melanoma that has recurred locally?

What, if any, is the role of immunotherapy in this situation ?

1 Answer available

How do you choose between single agent versus combination checkpoint inhibitors for BRAF Wildtype metastatic melanoma?

1 Answer available

How do you manage anticoagulation for patients with DVT/PE who have brain metastases?

Some medical oncologists tend to hold anticoagulation in patients who develop brain metastases for fear of causing intracranial hemorrhage. Is t...

3 Answers available

Would you ever consider stopping immunotherapy in a patient with metastatic melanoma after achieving a good response?

Would your recommendations change if it was a partial vs complete radiographic response?

1 Answer available

How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?

What immunosuppressive agents are used and in what order? Does your approach differ depending on the organ involved, e.g. colitis vs. pneumoniti...

1 Answer available

For newly diagnosed BRAF mutated melanoma with brain metastases, do you prefer to start with targeted therapy or with immunotherapy?

1 Answer available

Would you use immune checkpoint inhibitors in patients with well-compensated liver cirrhosis?

Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population? What about in patients with mild liv...

1 Answer available

How do you manage patients with BRAF V600E-mutated metastatic melanoma who have a mixed radiographic response after several months of therapy with dabrafenib/trametinib?

Does the site of progression or response matter? What if there is progression in the lungs but response in lymphadenopathy, for example?

1 Answer available

How do you manage hematologic toxicities in solid tumor patients treated with immune checkpoint inhibitors?

If these are presumed to be immune-mediated (e.g. immune neutropenia or immune thrombocytopenia), do you treat with steroids?

1 Answer available

How should RT be combined with immunotherapy to generate an abscopal response?

Is there any consensus regarding the optimal RT dose, fractionation, and timing to the best abscopal response? What is the optimal metastatic site to ...

1 Answer available

What should be the first line treatment for metastatic uveal melanoma?

1 Answer available

What is your approach to patients with stage III melanoma now that the FDA has approved adjuvant ipilimumab for high risk stage III melanoma patients?

1 Answer available

How do you manage dabrafenib fever?

Decrease the dose? Treatment break? Steroids?

1 Answer available

When should patients with metastatic melanoma be referred for treatment at an academic center?

With novel therapies quickly evolving, it's becoming more difficult to discern the proper sequence of therapies and the point at which a clinical tria...

1 Answer available

Papers discussed in this category

Oral oncology, 2018-03

Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis.

J. Clin. Oncol., 2018 Mar 14

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Blood, 2015-07-23

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

Eur. J. Cancer, 2016-02-01

Immunotherapy, 2016-10

Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.

J. Clin. Oncol., 2018-06-10

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

N Engl J Med, 2015 May 31

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

International journal of radiation oncology, biology, physics, 2016-06-01

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

The New England journal of medicine, 2017-11-09

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

N. Engl. J. Med., 2017-11-09

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

The Lancet. Oncology, 2016-11

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

The New England journal of medicine, 2017-10-05

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Lancet (London, England), 2017-10-21

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Lancet Oncol, 2018 May

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

The Lancet. Oncology, 2016-10

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

N Engl J Med, 2018 Apr 15

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Lancet Oncol, 2022 Oct 18

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

Lancet Oncol., 2017 Mar 04

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Journal for immunotherapy of cancer, 2019-06-06

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

J. Clin. Oncol., 2019 Feb 27

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Melanoma research, 2015-04

The emerging role of radiotherapy for desmoplastic melanoma and implications for future research.

Nature, 2018-01-18

High response rate to PD-1 blockade in desmoplastic melanomas.

Cureus, 2019 Jun 18

Desmoplastic Melanoma: Clinical Characteristics and Survival in the US Population.

PloS one, 2015

Clinicopathologic predictors of survival in patients with desmoplastic melanoma.

Semin. Cancer Biol., 2019 Jul 19

Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

J Natl Compr Canc Netw,

Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.

J. Clin. Oncol., 2019 Dec 27

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Lancet (London, England), 2004-05-22

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

The Lancet. Oncology, 2016-07

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

International journal of radiation oncology, biology, physics, 2018-03-15

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

The New England journal of medicine, 2018-08-23

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-01

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

J. Clin. Oncol., 2019 Sep 25

Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.

Clin Oncol (R Coll Radiol),

Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases.

Lancet Oncol., 2018 Mar 27

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Cochrane Database Syst Rev, 2012 Apr 18

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Cancer, 2016 Jun 10

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.

International journal of radiation oncology, biology, physics, 2017-11-15

Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).

International journal of radiation oncology, biology, physics, 1997-03-01

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.

Neurosurgery, 2020 Apr 21

Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases.

JAMA ophthalmology, 2016-08-01

Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.

N Engl J Med, 2022 Sep 12

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

Front Oncol, 2023 Jan 04

Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma.

Br J Dermatol, 2015 Aug 08

Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.

N Engl J Med, 2019 Sep 28

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Melanoma research, 2017-06

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.

JAMA Dermatol,

Prevalence and Gross Morphologic Features of Perianal Melanocytic Nevi.

Pathology, 2018 Nov 26

Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.

Semin Cancer Biol, 2019 Oct 23

The mutational landscape of mucosal melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-01

Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma.

BJS open, 2021 Nov 09

Surgical treatment of anorectal melanoma: a systematic review and meta-analysis.

Head Neck, 2021 Jun 07

Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review.

Nature medicine, 2023 Aug 17

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Feb 13

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.

Ann Pharmacother, 2021 Jul 20

Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.

Ann Transl Med,

The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Can Fam Physician,

Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.

J Clin Oncol, 2022 Sep 27

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

J Clin Oncol, 2022 Jan 14

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.

Eur J Cancer, 2021 Nov 17

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

J Immunother Cancer, 2020 Dec

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in -mutant melanoma.

N Engl J Med,

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

Melanoma research, 2017-10

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Cancer, 2011-04-15

Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 Sep 09

Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment.

European journal of cancer (Oxford, England : 1990), 2017-04

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

American journal of clinical oncology, 2005-12

Head and neck mucosal melanoma.

Head & neck, 2016-01

Update on primary head and neck mucosal melanoma.

The Laryngoscope, 1994-02

Mucosal melanoma of the head and neck: the impact of local control on survival.

Oral and maxillofacial surgery, 2023 Apr 05

Head and neck mucosal melanoma: radiological considerations and UK imaging guidelines.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-05-01

Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Asia-Pacific journal of clinical oncology, 2020 Aug 05

The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary.

Annals of surgical oncology, 2020 May 13

Patterns of Metastasis in Merkel Cell Carcinoma.

J Clin Oncol, 2020 Nov 20

Systemic Therapy for Melanoma: ASCO Guideline.

Lancet Oncol, 2015 Mar 31

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Lancet, 2022 Sep 10

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.

Annals of surgery, 2006-12

The role of abdominoperineal resection as surgical therapy for anorectal melanoma.

Annals of surgical oncology, 2013-07

Locoregional lymphadenectomy in the surgical management of anorectal melanoma.

Annals of surgical oncology, 2010-01

Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?

Diseases of the colon and rectum, 1999-09

Changing epidemiology of anorectal melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-10

Somatic activation of KIT in distinct subtypes of melanoma.

Dermatol Pract Concept, 2019 Jan 31

Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters.

Clin Cancer Res, 2013 Jul 05

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Oct 30

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.

The Lancet. Oncology, 2019 May 31

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Nature, 2022 Oct 26

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Dec 01

Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases.

Cancer, 2023 Mar 04

Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.

Journal for immunotherapy of cancer, 2022 Aug

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.

N Engl J Med, 2017 Jun 8

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Journal of the American Academy of Dermatology, 2019 Dec 10

Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.

The oncologist, 2021 May 31

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.

Medical Oncology

Melanoma/Skin Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology